0000899243-21-011978.txt : 20210316
0000899243-21-011978.hdr.sgml : 20210316
20210316171343
ACCESSION NUMBER: 0000899243-21-011978
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210313
FILED AS OF DATE: 20210316
DATE AS OF CHANGE: 20210316
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cao Yanling
CENTRAL INDEX KEY: 0001789665
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39067
FILM NUMBER: 21746943
MAIL ADDRESS:
STREET 1: SUITE 1518, TWO PACIFIC PLACE
STREET 2: 88 QUEENSWAY
CITY: HONG KONG
STATE: K3
ZIP: 00000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viela Bio, Inc.
CENTRAL INDEX KEY: 0001734517
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 240-558-0038
MAIL ADDRESS:
STREET 1: 1 MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-13
1
0001734517
Viela Bio, Inc.
VIE
0001789665
Cao Yanling
C/O VIELA BIO, INC.,
ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO
GAITHERSBURG
MD
20878
1
0
1
0
Common Stock
2021-03-13
4
D
0
8322353
53.00
D
0
I
Held by Boundless Meadow Limited
Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger, each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
Boundless Meadow Limited is wholly owned by Boyu Capital Fund III. L.P., which is a fund to which Boyu Capital Advisory Co. Limited provides non-discretionary investment advisory services. Mr. Cao is a Partner of Boyu Capital Advisory Co. Limited, and may be deemed to beneficially own the shares held by Boundless Meadow Limited. Mr. Cao disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.
/s/ Yanling Cao
2021-03-16